Skip to main content
SpringerLink
Log in

Therapeutic Challenges

Prenatal and Paediatric Safety Considerations

  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Developmental changes make the fetus and child uniquely susceptible to drug toxicities which do not occur in mature individuals.

Passive exposure to maternally administered drugs during fetal life introduces the potential risk of morphological or behavioural teratogenesis. Although animal studies are useful in identifying potential teratogens, they are poor predictors of human teratogenesis.

Most drugs are excreted into breast milk in insufficient quantity to cause adverse effects in the nursing infant. However, there are several exceptions. Therefore, it is important to document the extent to which a drug appears in breast milk and is absorbed by the nursing infant prior to its use by the mother.

Plasticity of growing tissues and changes in body composition, the rate of drug metabolism, drug metabolic pathways and elimination rates during growth and development may alter susceptibility to unique drug toxicities. This requires that drug safety and efficacy be established in children at different ages.

Ethical and technical constraints inherent in drug studies in children introduce increased effort and cost. However, there is a moral imperative for academicians, government agencies and the pharmaceutical industry to work together to ensure that drugs intended for use in children are adequately tested in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 84: 924–936, 1989

    Google Scholar 

  • Assael BM, Parini R, Rusconi F, Cavanna G. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatric Research 16: 810–813, 1982

    Article  PubMed  CAS  Google Scholar 

  • Beckman DA, Brent RL. Mechanisms of teratogenesis. Annual Revue of Pharmacology and Toxicology 24: 483–500, 1984

    Article  CAS  Google Scholar 

  • Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. New England Journal of Medicine 261: 1318–1321, 1959

    Article  PubMed  CAS  Google Scholar 

  • Greenwald P, Barlow JJ, Nasea PC, Burnett WS. Vaginal cancer after maternal treatment with synthetic estrogens. New England Journal of Medicine 285: 390–392, 1971

    Article  PubMed  CAS  Google Scholar 

  • Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New England Journal of Medicine 284: 878–881, 1971

    Article  PubMed  CAS  Google Scholar 

  • Hiller JL, Benda GI, Rahatzad M, Allen JR, Culver DH, et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics 77: 500–506, 1986

    PubMed  CAS  Google Scholar 

  • Holmes LB. Human teratogens. In Transplacental effects on fetal health, pp. 177–191, Alan R. Liss, 1988

  • Kellogg CK, Guillet R. Developmental effects of neuroactive drugs. In Transplacental effects on fetal health, pp. 265–277, Alan R. Liss, 1988

  • Kimbrough RD. Review of toxicity of hexachlorophene, including its neurotoxicity. Journal of Clinical Pharmacology, November-December: 439–444, 1973

  • Lenz W, Knapp K. Die Thalidomid-Embryopathie. Deutsche Medizinische Wochenschrift 87: 1232–1242, 1962

    Article  PubMed  CAS  Google Scholar 

  • Lieh-Lai MW, Sarnaik AP, Newton JF, Miceli JN, Fleischmann LE, et al. Metabolism and pharmacokinetics of acetaminophen in a severely poisoned young child. Journal of Pediatrics 105: 125–128, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lischner H, Seligman SJ, Krammer A, Parmellee Jr AH. An outbreak of neonatal deaths among term infants associated with administration of chloramphenicol. Journal of Pediatrics 59: 21–25, 1961

    Article  PubMed  CAS  Google Scholar 

  • Martone WJ, Williams WW, Mortensen ML, Gaynes RP, White JW, et al. Illness with fatalities in premature infants: association with an intravenous vitamin E preparation, E-Ferol. Pediatrics 78: 591–600, 1986

    PubMed  CAS  Google Scholar 

  • Oski F. Kernicterus. In Schaffer AJ, Avery ME (Eds) Diseases of the newborn, pp. 661, W.B. Saunders, Philadelphia, 1977

    Google Scholar 

  • Stewart DJ. Prevalence of tetracyclines in children’s teeth — study II: resurvey after five years. British Medical Journal 3: 320–322, 1973

    Article  PubMed  CAS  Google Scholar 

  • Weicker H, Bachman KD, Pfeiffer RA, Gleiss J. Thalidomid-Embryopathie. Deutsche Medizinische Wochenschrift 33: 1597–1607, 1962

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology/Toxicology, Children’s Hospital of Michigan, Detroit, Michigan, 48201, USA

    Ralph E. Kauffman

Authors
  1. Ralph E. Kauffman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kauffman, R.E. Therapeutic Challenges. Drug-Safety 5 (Suppl 1), 65–70 (1990). https://doi.org/10.2165/00002018-199000051-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199000051-00010

Keywords

Search

Navigation